Please login to the form below
BMS-986205
This page shows the latest BMS-986205 news and features for those working in and with pharma, biotech and healthcare.
BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace
Suspends enrolment in BMS-986205 trials for NSCLC and head and neck cancer. ... Bristol-Myers Squibb hammered another nail in the coffin of IDO1 as a drug target in immuno-oncology yesterday after halting two trials of its BMS-986205 candidate acquired
Latest news
-
BMS boosts immuno-oncology with $2.3bn IFM buy
The big pharma has steadily added to its portfolio with a stream of candidates targeting molecules such as CD137 (urelumab), IDO (BMS-986205), and LAG-3 (BMS-986016) - all in phase ... Adding the new candidates "broadens our ability to investigate
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
